title: Autologous transplantation of bone marrow-derived mononuclear and CD133(+) cells in patients with decompensated cirrhosis.
abstract: BACKGROUND
  Cirrhosis, the end stage of progressive hepatic fibrosis, is characterized by distortion of the hepatic architecture and the formation of regenerative nodules. Liver transplantation is one of the few available therapies for such patients. However, due to a severe shortage of organ donors, surgical complications, transplant rejection and the high cost of this procedure much interest has focused on research to find new treatment modalities for this disease. There is accumulating evidence for the contribution of bone marrow stem cells to participate in liver regeneration.
  
  
  METHODS
  Here we report on six patients with end stage liver disease who were subjected to intraportal administration of autologous bone marrow-derived CD133(+) in comparison to mononuclear cells in short-term (6 months) and long-term (24 months) follow up.
  
  
  RESULTS
  There were no adverse effects in any of the patients during the short- and long-term follow up period. Moreover, there were no significant alterations of liver function parameters, liver enzymes, serum albumin, creatinine, serum bilirubin and/or liver volume after transplantation of both types of autologous cells in these patients.
  
  
  CONCLUSIONS
  Our study has shown both the safety and feasibility of this type of liver cell therapy and may be a bridge to liver transplantation. The trial was registered with NIH clinical trials (www.clinicaltrials.gov) as identifier: NCT00713934.
authors.affiliation: Shiraz Transplant Center, Namazi Hospital, Shiraz University of Medical Sciences, Iran.
authors.forename: Saman
authors.initials: S
authors.lastname: Nikeghbalian
authors.forename: Behshad
authors.initials: B
authors.lastname: Pournasr
authors.forename: Nasser
authors.initials: N
authors.lastname: Aghdami
authors.forename: Alireza
authors.initials: A
authors.lastname: Rasekhi
authors.forename: Bita
authors.initials: B
authors.lastname: Geramizadeh
authors.forename: Seyed Mohammad Kazem
authors.initials: SM
authors.lastname: Hosseini Asl
authors.forename: Mani
authors.initials: M
authors.lastname: Ramzi
authors.forename: Farzad
authors.initials: F
authors.lastname: Kakaei
authors.forename: Mehrnaz
authors.initials: M
authors.lastname: Namiri
authors.forename: Reza
authors.initials: R
authors.lastname: Malekzadeh
authors.forename: Ahmad
authors.initials: A
authors.lastname: Vosough Dizaj
authors.forename: Seyed Ali
authors.initials: SA
authors.lastname: Malek-Hosseini
authors.forename: Hossein
authors.initials: H
authors.lastname: Baharvand
mesh_terms: D000071916:AC133 Antigen; D000328:Adult; D015703:Antigens, CD; D016026:Bone Marrow Transplantation; D058625:End Stage Liver Disease / Q000209:etiology / Q000601:surgery*; D005260:Female; D005500:Follow-Up Studies; D006023:Glycoproteins; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D007262:Infusions, Intravenous; D008103:Liver Cirrhosis / Q000150:complications / Q000601:surgery*; D008111:Liver Function Tests; D008115:Liver Regeneration; D008297:Male; D009000:Monocytes / Q000276:immunology*; D010455:Peptides; D011169:Portal Vein; D014182:Transplantation, Autologous; D016896:Treatment Outcome
chemical_list: D000071916:AC133 Antigen; D015703:Antigens, CD; D006023:Glycoproteins; C000606023:PROM1 protein, human; D010455:Peptides